MedTrace Logo

Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)

NCT05488613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2022-11-08

No results posted yet for this study

Summary

This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

Midostaurin

Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2021-01-26
Completion
2021-01-26

Countries

  • Finland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488613 on ClinicalTrials.gov